Trilliome is a biotech startup pioneering precision prebiotics that supports healthy aging by modulating the microbiome and enhancing gut-brain resilience. Its upcycled exotic plant bioactives and AI-driven gut models precisely modulate and boost hard-to-reach gut bacteria linked to cognitive and metabolic health. Backed by ETH Zurich and the University of Basel, Trilliome scales through B2B ingredient licensing, ingredient white-label sales and co-development. With strong early traction and patent-pending IP, Trilliome is bringing science-backed, next-gen prebiotics to the global health market.